Literature DB >> 21283098

Hepatitis C--pipeline update.

Irena Melnikova.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21283098     DOI： 10.1038/nrd3361

Source DB:  PubMed          Journal:  Nat Rev Drug Discov        ISSN： 1474-1776            Impact factor:   84.694


× No keyword cloud information.
  2 in total

Review 1.  Resistance to direct antiviral agents in patients with hepatitis C virus infection.

Authors:  Christoph Sarrazin; Stefan Zeuzem
Journal:  Gastroenterology       Date:  2009-12-16       Impact factor: 22.682

2.  Diagnosis, management, and treatment of hepatitis C: an update.

Authors:  Marc G Ghany; Doris B Strader; David L Thomas; Leonard B Seeff
Journal:  Hepatology       Date:  2009-04       Impact factor: 17.425
  2 in total
  9 in total

1.  A macrocyclic HCV NS3/4A protease inhibitor interacts with protease and helicase residues in the complex with its full-length target.

Authors:  Nikolaus Schiering; Allan D'Arcy; Frederic Villard; Oliver Simic; Marion Kamke; Gaby Monnet; Ulrich Hassiepen; Dmitri I Svergun; Ruth Pulfer; Jörg Eder; Prakash Raman; Ursula Bodendorf
Journal:  Proc Natl Acad Sci U S A       Date:  2011-12-12       Impact factor: 11.205

Review 2.  Antiviral treatment to prevent chronic hepatitis B or C-related hepatocellular carcinoma.

Authors:  Li-Ping Chen; Jun Zhao; Yan Du; Yi-Fang Han; Tong Su; Hong-Wei Zhang; Guang-Wen Cao
Journal:  World J Virol       Date:  2012-12-12

3.  Identification of PTC725, an orally bioavailable small molecule that selectively targets the hepatitis C Virus NS4B protein.

Authors:  Zhengxian Gu; Jason D Graci; Frederick C Lahser; Jamie J Breslin; Stephen P Jung; James H Crona; Patricia McMonagle; Ellen Xia; Shaotang Liu; Gary Karp; Jin Zhu; Song Huang; Amin Nomeir; Marla Weetall; Neil G Almstead; Stuart W Peltz; Xiao Tong; Robert Ralston; Joseph M Colacino
Journal:  Antimicrob Agents Chemother       Date:  2013-04-29       Impact factor: 5.191

4.  Imidazopyridine-Based Fatty Acid Synthase Inhibitors That Show Anti-HCV Activity and in Vivo Target Modulation.

Authors:  Johan D Oslob; Russell J Johnson; Haiying Cai; Shirley Q Feng; Lily Hu; Yuko Kosaka; Julie Lai; Mohanram Sivaraja; Samnang Tep; Hanbiao Yang; Cristiana A Zaharia; Marc J Evanchik; Robert S McDowell
Journal:  ACS Med Chem Lett       Date:  2012-12-02       Impact factor: 4.345

5.  Interactions of ketoamide inhibitors on HCV NS3/4A protease target: molecular docking studies.

Authors:  Abdul Wadood; Muhammad Riaz; Syed Babar Jamal; Masaud Shah
Journal:  Mol Biol Rep       Date:  2014-01       Impact factor: 2.316

6.  Molecular docking study of P4-Benzoxaborolesubstituted ligands as inhibitors of HCV NS3/4A protease.

Authors:  Abdul Wadood; Muhammad Riaz; Syed Babar Jamal; Masaud Shah; Muhammad Arif Lodhi
Journal:  Bioinformation       Date:  2013-03-19

7.  Apolipoprotein E mediates attachment of clinical hepatitis C virus to hepatocytes by binding to cell surface heparan sulfate proteoglycan receptors.

Authors:  Jieyun Jiang; Xianfang Wu; Hengli Tang; Guangxiang Luo
Journal:  PLoS One       Date:  2013-07-02       Impact factor: 3.240

8.  Computational study on the inhibitor binding mode and allosteric regulation mechanism in hepatitis C virus NS3/4A protein.

Authors:  Weiwei Xue; Ying Yang; Xiaoting Wang; Huanxiang Liu; Xiaojun Yao
Journal:  PLoS One       Date:  2014-02-25       Impact factor: 3.240

9.  In silico identification and evaluation of leads for the simultaneous inhibition of protease and helicase activities of HCV NS3/4A protease using complex based pharmacophore mapping and virtual screening.

Authors:  Abdul Wadood; Muhammad Riaz; Reaz Uddin; Zaheer Ul-Haq
Journal:  PLoS One       Date:  2014-02-13       Impact factor: 3.240
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.